Leerink Swann assumed coverage on shares of Hookipa Pharma (NASDAQ:HOOK) in a research note published on Monday, Benzinga’s Daily Ratings Newsletter reports. The brokerage issued an outperform rating and a $20.00 price objective on the stock.
Other equities research analysts have also issued research reports about the company. Bank of America initiated coverage on Hookipa Pharma in a research report on Monday. They set a buy rating and a $17.00 price target on the stock. Svb Leerink initiated coverage on Hookipa Pharma in a research report on Monday. They set an outperform rating and a $20.00 price target on the stock. Finally, Royal Bank of Canada initiated coverage on shares of Hookipa Pharma in a report on Monday. They set an outperform rating and a $23.00 target price on the stock.
NASDAQ HOOK opened at $12.83 on Monday. Hookipa Pharma has a one year low of $12.30 and a one year high of $14.76.
Hookipa Pharma Company Profile
HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.
Featured Article: Candlestick
Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.